Top 20 Life Science Startup Investors in Singapore (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Antler
VC Fund
|
2 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $108k–$28M |
|
Eisai
VC Fund
|
2 | United States, Japan, China | Series A, Seed, Series C | Medical, Biotechnology, Health Care | $3M–$794M |
|
Nestle
VC Fund
|
1 | United States, United Kingdom, Germany | Corporate Round, Grant, Private Equity | Food and Beverage, Health Care, Food Processing | $6k–$3.8B |
|
Anzu Partners
VC Fund
|
1 | United States, Canada, Spain | Series A, Series B | Biotechnology, Software, Manufacturing | $5M–$55M |
|
Amgen Ventures
VC Fund
|
1 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $3.5M–$110M |
|
Seeds Capital
VC Fund
|
1 | Singapore, United States, Hong Kong | Seed, Series A | Software, Biotechnology, Health Care | $767k–$24M |
|
Hana Financial Investment
VC Fund
|
1 | South Korea, Singapore, India | Series A, Series B, Seed | Information Technology, Biotechnology, Software | $383k–$25M |
|
Prox Ventures
VC Fund
|
1 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
IBK Capital
VC Fund
|
1 | South Korea, United States, India | Series A, Seed, Series B | Health Care, Biotechnology, Information Technology | $2k–$21M |
|
EDBI
VC Fund
|
1 | United States, Singapore, India | Series C, Series B, Series D | Biotechnology, Software, Health Care | $12M–$400M |
|
The Venture Collective
VC Fund
|
1 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Artificial Intelligence | $410k–$32M |
|
Lightstone Ventures
VC Fund
|
1 | United States, Ireland, Singapore | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7M–$105M |
|
M Capital Partners
VC Fund
|
1 | France, United States, Canada | Seed, Series A | Health Care, Software, Food and Beverage | $1.1M–$7.7M |
|
K3 Ventures
VC Fund
|
1 | Singapore, United States, Indonesia | Series A, Seed | Financial Services, FinTech, Software | $1.2M–$42M |
|
SK Securities
VC Fund
|
1 | South Korea, United States, Singapore | Series A, Seed, Series B | Apps, Health Care, Information Technology | $3k–$24M |
|
Partners Investment
VC Fund
|
1 | South Korea, United States, Japan | Series A, Series B, Series C | Biotechnology, Health Care, Software | $2.1M–$117M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
1 | Japan, United States, India | Seed, Series A | Health Care, Biotechnology, Medical | $3.1M–$78M |
|
Altara Ventures
VC Fund
|
1 | Indonesia, Singapore, Philippines | Series A, Series B, Series C | FinTech, Software, Financial Services | $3.9M–$70M |
|
Temasek
VC Fund
|
1 | United States, China, India | Series B, Series C, Series D | Biotechnology, Health Care, Software | $29M–$460M |
|
KB Financial Group
VC Fund
|
1 | South Korea, India, Vietnam | Series A, Series B, Seed | Software, Financial Services, SaaS | $1M–$104M |
| Access all 47 investors in Singapore Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 1818
- Round size: Seed $186k–$4.6M; Pre-Seed $108k–$750k; Series A $4.6M–$28M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
- Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Eisai is a human healthcare company that provides products and services to its patients and their families under any healthcare system. They specialize in an integrated pharmaceutical business that operates in business groups and focuses on oncology and neurology, dementia-related diseases, and neurodegenerative diseases.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Series A, Seed, Series C
- Geography: United States, Japan, China
Investor stats
- Total investments: 17
- Round size: Series A $3M–$794M; Series C $46M–$100M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- RecoMed — Find the best doctors and dentists. Search by location or by speciality, and find the right doctor for you.
- Seed Therapeutics — SEED Therapeutics designs molecular glue degraders using the full E3 ligase universe to eliminate disease proteins across oncology and beyond.
- Beren Therapeutics — Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA.
Nestle manufactures and sells food and beverages for several countries. It has generated more than CHF 90 billion in annual revenue. Its diverse product portfolio includes brands such as Nestle, Nescafe, Perrier, Pure Life, and Purina. Nestle also owns just over 23% of French cosmetics firm L'Oréal. It has a vast portfolio of global products,with 34 brands each achieving more than CHF 1 billion in sales annually and a geographic presence that spans 189 countries.
Show more...Investment focus
- Industry: Food and Beverage, Health Care, Food Processing
- Stage:Corporate Round, Grant, Private Equity
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 20
- Round size: Grant $6k–$150k; Private Equity $130M–$3.8B; Corporate Round $100M–$229M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Drools — Discover Drools, the best dog food brand offering premium nutrition for your furry friend. Explore our range of healthy, vet-recommended dog food to keep your pet happy and healthy.
- Wonder — Introducing a new kind of home dining experience. Currently available in areas of New Jersey.
- Hsu Fu Chi — Hsu Fu Chi is a confectionery company that manufactures various confectionaries, biscuits, chocolates, jellies, sachima, and snacks.
Anzu Partners invests in breakthrough clean tech, industrial, and life science technologies with $1B in assets under management across venture, credit, and public structures.
Show more...Investment focus
- Industry: Biotechnology, Software, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Spain
Investor stats
- Total investments: 77
- Round size: Series A $6M–$25M; Series B $5M–$55M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- ImmunoScape — ImmuniScape discovers and develops novel TCR-based therapeutics against solid tumors
- AM Batteries — AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology. The company was founded in 2016 and is headquartered in Chelmsford, Massachusetts.
- South 8 Technologies — South 8's LiGas cells are engineered to deliver unmatched performance and safety in the most demanding environments.
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 110
- Round size: Series A $3.5M–$42M; Series B $11M–$110M; Series C $19M–$80M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $100M in 2012
Portfolio highlights
- Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Mindset Medical — Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 140
- Round size: Seed $767k–$6M; Series A $3.5M–$24M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Pints AI — Unlock global and private financial data with AI like never before.
- HealthBeats — HealthBeats is a product based on their belief,regular monitoring outside of healthcare settings will only lead to better results.
- Protuoso Biosciences — Protuoso Biosciences is a biotechnology company developing next-generation multifunctional biologics designed to address complex disease biology.
Hana Financial Investment Company Limited offers brokerage, securities dealing, underwriting, mutual funds, and online trading services
Show more...Investment focus
- Industry: Information Technology, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: South Korea, Singapore, India
Investor stats
- Total investments: 91
- Round size: Seed $383k–$7.9M; Series A $1.9M–$25M; Series B $1.6M–$25M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Trustay — Trustay is a real estate asset management company.
- earlysloth — Earlysloth is an AI based survey on the messenger for the enterprise.
- Kimu Studio — Kimu discovers servant artists, plans education and exhibitions with the artist's unique sensibility.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 79
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group —
IBK Capital is the venture capital arm of the Industrial Bank of Korea (IBK).
Show more...Investment focus
- Industry: Health Care, Biotechnology, Information Technology
- Stage:Series A, Seed, Series B
- Geography: South Korea, United States, India
Investor stats
- Total investments: 111
- Round size: Seed $2k–$7.6M; Series A $720k–$8.2M; Series B $7k–$21M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Willog — As a fast-growing startup, Willog provides a “item-level condition monitoring” that innovates the supply chain of sensitive, perishable or valuable goods where condition monitoring is required, and its efforts are to create a transparent and connected logistics flow. Based on its patented sensor technology and its cloud-based software, Willog helpscompanies gain seamless visibility down to the item-level and control over their shipments across their supply chain so they can have condition foresights and insights to improve their bottom line.Willog acquired 25 enterprise customers including MNCs like Hyundai Motor Group and DHL Express since its establishment. Willog is rapidly expanding its presence in various industries including bio-pharmaceutical, fresh food, and special logistics, where condition monitoring is key to business continuity. Going forward, while strengthening its leadership position in Korea, Willog will accelerate global expansion with partnerships in America, Kazakhstan, and Malaysia.
- Automata — Automata creates AI-powered tools like AI agents and smart integrations that simplify how teams plan, communicate, and work. The company solves business problems by enabling AI to build, manage, and evolve software workflows while humans guide the AI to deliver real value.Automata provides industry-tailored AI solutions
- PEOPLE & TECHNOLOGY — PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector.More than 100 corporate customers in various business sectorssuch as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas.
EDBI invests in high growth technology sectors. EDBI Creates value and empowers companies to build sustainable legacies.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series C, Series B, Series D
- Geography: United States, Singapore, India
Investor stats
- Total investments: 192
- Round size: Series B $19M–$170M; Series C $12M–$275M; Series D $17M–$400M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Paxata — The DataRobot End-of-Life (EOL) policy helps manage product lifecycle phases in a way that is transparent and clear for customers who will seamlessly transition to a new product or service.
- Endowus — Licensed by MAS. Grow all your money through intelligent investment portfolios built by experts, customised to your goals. Award-winning fee-only wealth platform.
- Sleek — All-in-one business finances and admin for business owners, SMEs and investors in Singapore. Get started with our 100% online platform.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!TVC is a transformational, early-stage venture firm backed by world class entrepreneurs and business leaders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 55
- Round size: Seed $2.7M–$20M; Pre-Seed $410k–$1.9M; Series A $10M–$32M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Orbem — Transform biological imaging with AI-powered MRI technology. Non-invasive solutions for poultry, fruits, nuts, and health. Building a sustainable future.
- Cocoon — Low carbon construction materials for the builders of tomorrow.
- Unnatural Products — Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California.
Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing inbreakthrough life science companies during a time of unique opportunity in space.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 84
- Round size: Series A $7M–$102M; Series B $18M–$100M; Series C $20M–$105M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
- Psivant Therapeutics — Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services.
- Crystalys Therapeutics — Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
M Capital is an independent investment company with +€500m AuM. A unique hub where entrepreneurs can have an equity finance and quasi-equity as well as a permanent support to accelerate their growth. In 2020, M Capital has funded over 200 French companies.
Show more...Investment focus
- Industry: Health Care, Software, Food and Beverage
- Stage:Seed, Series A
- Geography: France, United States, Canada
Investor stats
- Total investments: 109
- Round size: Seed $1.1M–$5.2M; Series A $3.3M–$7.7M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Demether — Demether is a DeFi protocol that works to enable zero-cost access to TVL for blockchains.
- MilkStraw AI — Saving companies up to 75% on AWS
- The Sanctuary Group — The Sanctuary Group provides aqua-cycling, indoor cycling, boxing bootcamp, yoga, dance cardio, HIIT workouts, and kids’ swim classes.
K3 Ventures provides venture capital for technology startups in various sectors such as finance, education, healthcare, food and agriculture and others. The firm is headed by Kuok Meng Xiong.
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Series A, Seed
- Geography: Singapore, United States, Indonesia
Investor stats
- Total investments: 93
- Round size: Seed $1.2M–$20M; Series A $2M–$42M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- iEduGPT — iEduGPT is an AI-powered learning platform based in Singapore that offers personalized, adaptive learning solutions for professional and academic exam preparation. It leverages artificial intelligence to analyze individual learners' strengths and knowledge gaps and create optimized study paths. The platform aims to transform exam preparationby making learning smarter, more efficient, and tailored to each user’s unique needs, covering certifications in finance, academics, and languages.
- Rekosistem — Rekosistem is a Clean- & Climate-Tech Company that enables circular economy implementation in the waste supply chain by leveraging proprietary waste management operation systems to transform waste into recycled materials and renewable resources.
- Octopus Power — Octopus Power develops physics-based artificial intelligence systems focused on physical AGI, enabling machines to perceive, reason, and act within real-world environments. The company builds models that integrate physical laws with data-driven learning to support embodied intelligence, allowing systems to interact with and adapt to dynamicphysical conditions. Its technology is designed to move beyond purely digital AI by incorporating simulation, control systems, and real-world feedback loops into intelligent decision-making.The platform supports applications in robotics, industrial automation, and complex physical systems where understanding motion, force, and environmental constraints is essential. It leverages continuous learning mechanisms that allow systems to evolve over time, improving performance through interaction and data accumulation. Octopus Power also develops infrastructure for training and deploying these models, including simulation environments and tools for integrating AI with physical hardware.
SK Securities is a South Korea-based financial service provider that specializes in the securities market. It primarily engaged in securities brokerage, dealing and underwriting businesses, covering stocks, futures, options, government bonds, corporate bonds, foreign exchanges, and financial derivative products. The company also involves in theinvestment banking business, which provides acquisition, project financing services, and wealth management services.SK Securities was founded in 1955.
Show more...Investment focus
- Industry: Apps, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: South Korea, United States, Singapore
Investor stats
- Total investments: 50
- Round size: Seed $297k–$2.2M; Series A $3k–$24M; Series B $5k–$12M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Quantum AI — Quantum AI is an AI data company that offers offline and online data collection and analysis services.
- Gadget Korea — Gadget korea offers data roaming services.
- Buysell Standards — Buysell Standards is the provider of manpower supply and employment arrangement services.
As a responsible and long-term partner, they aim to make various constructive contributions to portfolio companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: South Korea, United States, Japan
Investor stats
- Total investments: 126
- Round size: Series A $2.1M–$26M; Series B $5.2M–$117M; Series C $7.4M–$87M
- Lead/follow: 11% lead, 89% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- XCENA — XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing.
- Solivis — Solivis is a solid electrolyte company that develops secondary batteries for next-generation electric vehicles.
- Cenyx Biotech — Cenyx Biotech develops diagnostic and therapeutic nano-compounds formed based on nanozymes and nanoparticles.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: Japan, United States, India
Investor stats
- Total investments: 182
- Round size: Seed $3.1M–$48M; Series A $3.6M–$78M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Flosfia — FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices.
- TXP Medical — TXP Medical build a next-generation medical system through acute care.
- Startbahn — Startbahn develops Startrail, a sustainable and scalable blockchain infrastructure that assures the reliability, authenticity, and traceability of artworks.
Singapore-based venture firm backing Series A & B companies across Southeast Asia. Built by operators for founders who understand the long climb. Global perspective, local instincts.
Show more...Investment focus
- Industry: FinTech, Software, Financial Services
- Stage:Series A, Series B, Series C
- Geography: Indonesia, Singapore, Philippines
Investor stats
- Total investments: 24
- Round size: Series A $4.5M–$13M; Series B $3.9M–$40M; Series C $12M–$70M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- FreeAgent CRM — We help teams to get everything in one place and work collaboratively to get more done while tracking and improving performance.
- Netbank — Netbank provides various banking solutions like alternative lenders, payment solutions, neobanks, and wallets.
- PolicyStreet — Renew your insurance and road tax instantly, hassle-free. We're the BEST, but don't just take our word for it. See what our happy customers have to say!
Temasek is a global investment company headquartered in Singapore with a multinational staff of over 960 people. Our portfolio is valued at S$434 billion.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series C, Series D
- Geography: United States, China, India
Investor stats
- Total investments: 455
- Round size: Series B $29M–$250M; Series C $35M–$400M; Series D $45M–$460M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- Xforceplus — Xforceplus develops enterprise collaborative solutions of software as a service. The company provides internet-based and cloud-innovated supply chain collaboration and invoice management software encompassing supply chain settlement, real-time electronic account, tax reporting, tax analysis, electronic invoicing, and other related areas, enablingbusinesses to increase tax revenue, release capital vitality, and ensure financial security.
- Impossible Foods — Impossible Foods focuses on developing plant-based substitutes for meat, dairy, and fish products. It selects specific proteins and nutrients from greens, seeds, and grains to recreate the experience of meats and dairy products. Founded by Patrick Brown and Monte Casino in 2011, Impossible Foods is headquartered in Redwood City, California.
- LeapFrog Investments — Scaling purpose-driven businesses to achieve leaps of growth, profitability and impact.
KB Financial Group is Korea’s leading financial institution with the largest customer base and the most extensive branch network in the country. With total assets exceeding US$342 billion, the Group wields a solid capital prowess and enjoys a strong brand loyalty. As of December 2012, the Group has ten domestic subsidiaries--banking, credit cards,securities, life insurance, asset management, real estate trust, venture capital, credit information, data system, and savings bank--and four overseas subsidiaries in Hong Kong, England, Cambodia, and China.KB Financial Group was established in September 2008 with extensive stock transfers from major subsidiary companies. The Group’s establishment was to better deal with such fundamental changes in the financial markets at home and abroad as the rapid globalization of financial service, a declining profitability of traditional banking operations, new industry regulations, and an increasing demand for comprehensive financial services.
Show more...Investment focus
- Industry: Software, Financial Services, SaaS
- Stage:Series A, Series B, Seed
- Geography: South Korea, India, Vietnam
Investor stats
- Total investments: 12
- Round size: Series A $1M–$45M; Series B $7.4M–$104M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Nitra — Nitra offers expense management software that integrates with the banks to provide innovative loan products.
- Wavebridge — Wavebridge is a top institutional digital asset company with traditional financial knowhows and crypto finance technology. The company was established in November 2018 to provide a comprehensive suite of investment solutions utilizing its data processing and AI technology.
- BlockOdyssey — BlockOdyssey is a tech start-up that provides 'blockchain-based B2B solutions'.Currently, the main solution is supplying 'blockchain-based anti-counterfeiting solution', and logistics & distribution history management is in progress with blockchain. It has received investment from Asia's largest cosmetic company, andis conducting business with French pharmaceutical companies.
Life Science Investor funding in Singapore at a glance
Stats across 28 deals from 47 investors.
Access all 47 investors in Singapore Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Singapore investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 47 investors investing in Singapore Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!